Clinical trials: Metastatic Colorectal Carcinoma
Colorectal Cancer, Metastatic Cancer
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
A study investigating if analysis of circulating tumor DNA (ctDNA) can guide adjuvant treatment in patients with advanced colorectal cancer (CRC)
- Trial name
- OPTIMISE (NCT04680260)
- Testing
- Standard of care, Circulating tumor DNA guided treatment approach
- Where
- 2 sites in Denmark
- Volunteers
- 350 people
- Sponsor
- Karen-Lise Garm Spindler
Colorectal Cancer
Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases
Eicosapentaenoic acid (EPA) is a naturally occuring omega-3 polyunsaturated fatty acid found in oily fish. EPA has anti-colorectal (bowel) cancer activity in experimental models.
- Trial name
- EMT (NCT01070355)
- Testing
- Eicosapentaenoic acid free fatty acid
- Where
- United Kingdom
- Volunteers
- 88 people
- Sponsor
- University of Leeds
Colorectal Neoplasms
Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients
This study makes an observation over the objective response rate of Apatinib and XELOX combination regimen in the first-line treatment of metastatic colorectal cancer.
- Trial name
- NCT02829385
- Testing
- Apatinib and XELOX combined treatment group
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Shoucheng Ma
Colorectal Cancer, Head and Neck Cancer
NGR-TNF in Treating Patients With Advanced Solid Tumors
RATIONALE: Targeted therapy with tumor necrosis factor combined with a fusion protein may stop the growth of solid tumors by stopping blood flow to the tumor.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00098943
- Testing
- CNGRC peptide-TNF alpha conjugate
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 70 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer, Stomach Cancer
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen (CEA)-positive advanced malignant solid tumors…
- Conditions
- Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Cancer
- Trial name
- NCT06821048
- Testing
- Intraperitoneal infusion of FAST CEA-targeted CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Weijia Fang, MD
Potentially Resectable Liver Metastasis From CRC, Colorectal Cancer
Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)
This is a single arm, open-label phase II study to evaluate the efficacy and safety of Capecitabine plus oxaliplatin (XELOX) in the peri-operative treatment of patients with potentially resectable liver metastasis from colorectal…
- Trial name
- NCT00997685
- Testing
- Capecitabine plus oxaliplatin
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Guangdong Provincial People's Hospital
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing.
- Trial name
- NCT00023868
- Testing
- FOLFIRI regimen, cisplatin, doxorubicin hydrochloride
- Where
- 9 sites in United States
- Sponsor
- American College of Radiology Imaging Network
Colorectal Cancer Metastatic
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of galunisertib/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant CRC.
- Trial name
- EORTC1615 (NCT03470350)
- Testing
- Galunisertib
- Where
- Netherlands
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer
Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- TRIBE (NCT00719797)
- Testing
- bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- 44 sites in Italy
- Volunteers
- 509 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Microsatellite Stable Metastatic Colorectal Cancer
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
To improve the survival in patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) by loco-regional therapy with personalized ultra-fractionated radiation plus immunotherpy.
- Trial name
- iPULSAR-CRC (NCT06841159)
- Testing
- Ultra-fractionated radiation therapy, Sintilimab, Standard systemic therapy
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer, Pancreas Cancer
T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
This phase I trial studies the side effects and best dose of autologous CD8+ and CD4+ transgenic T cells expressing high affinity KRASG12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) and to see how well they work in…
- Conditions
- Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
- Trial name
- NCT06043713
- Testing
- Bendamustine, Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fred Hutchinson Cancer Center
Colorectal Cancer Metastatic
Radioembolization in Elderly/ Fragile Patients With mCRC
Radioembolization (RE) is a minimally invasive treatment with administration of radioactive microspheres into the hepatic artery via a microcatheter.
- Trial name
- CAIRO7 (NCT05092880)
- Testing
- radioembolization, Standard of care first-line systemic therapy
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- UMC Utrecht
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
- Trial name
- NCT05462717
- Testing
- RMC-6291
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 222 people
- Sponsor
- Revolution Medicines, Inc.
Colorectal Cancer, Metastatic Colon Cancer
SGM-101 in Colorectal Lung Metastases
Near-infrared fluorescence-guided oncologic surgery (FGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness.
- Trial name
- SGM-CLM (NCT04737213)
- Testing
- SGM-101
- Where
- 2 sites in Netherlands
- Volunteers
- 10 people
- Sponsor
- Leiden University Medical Center
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT07066657
- Testing
- MRG007, MRG007 and Bevacizumab
- Where
- 21 sites in United States, China
- Volunteers
- 572 people
- Sponsor
- ArriVent BioPharma, Inc.
KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in…
- Trial name
- NCT07094113
- Testing
- AMG 410, Pembrolizumab, Panitumumab
- Where
- 39 sites in United States, Australia and 12 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of sintilimab and chidamide in combination with or without IBI305(bevacizumab) in patients with standard treatment failure of advanced or metastatic pMMR/MSS…
- Trial name
- NCT04724239
- Testing
- Sintilimab, Chidamide, IBI305
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer Metastatic
Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Combining Sorafenib with standard cytotoxic fluoropyrimidine therapy for advanced colorectal cancer may provide clinical benefit when no other treatment remains.
- Trial name
- SorCape (NCT01471353)
- Testing
- Sorafenib Plus Capecitabine (SorCape)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Florida
Ras-mutated Metastatic Colorectal Cancer, mCRC
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs.
- Conditions
- Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
- Trial name
- NCT07446322
- Testing
- Bevacizumab, FOLFIRI, Pelareorep
- Where
- 19 sites in United States
- Volunteers
- 60 people
- Sponsor
- Oncolytics Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.